UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO of United Therapeutics) exercised 9,500 stock options and sold 9,500 shares of UTHR common stock via a trust for roughly $4.8 million in total proceeds under a 10b5‑1 plan.

On August 13, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and on the same day sold those 9,500 shares in a series of open‑market transactions at prices ranging from approximately $500.08 to $512.36 per share. The gross sale proceeds were roughly $4.8 million, implying an economic spread of about $3.46 million before taxes and fees, and the transactions were executed pursuant to a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. After these transactions, the reporting person continued to hold substantial indirect ownership in United Therapeutics common stock through various family trusts, including 324,443 shares in the trust reflected in these trades, plus additional direct and indirect holdings disclosed in the filing.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000120

Alert Tier

7